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Abstract 
 
 
Background 
Evidence regarding the association between cannabis use and depression remain conflicting, 
especially as studies have not typically adopted a longitudinal design with a follow-up period 
that was long enough to adequately cover the risk period for onset of depression. 
 
Method 
Males from the Cambridge Study in Delinquent Development (CSDD) (N=285) were assessed 7 
times from age 8 to 48 years to prospectively investigate the association between cannabis use 
and risk of Major Depressive Disorder (MDD). A combination of multiple analyses (logistic 
regression, Cox regression, fixed-effects analysis) was employed to explore the strength and 
direction of effect within different developmental stages. 
 
 
Results 
Multiple regression analyses revealed that early onset cannabis use (before age 18) but not late 
onset cannabis use (after age 27) was associated with a higher risk and shorter time until a 
subsequent MDD diagnosis. This effect was present in high-frequency ([Odds Ratio (OR) 8.83, 
95% Confidence Interval (CI) 1.29-70.79]; [Hazard Ratio (HR) 8.69, 95%CI 2.07-36.52]) and 
low-frequency early-onset users ([OR2.41, 95%CI 1.22-4.76]; [HR2.09, 95%CI 1.16-3.74]). 
Effect of increased frequency of cannabis use on increased risk of subsequent MDD was 
observed only for use during adolescence (age 14-18) but not at later life stages, while 
controlling for observed and non-unobserved time-invariant factors. Conversely, MDD in 
adulthood (age 18-32) was linked to a reduction in subsequent cannabis use (age 32-48). 
 
 
Conclusions 
The present findings provide evidence implicating frequent cannabis use during adolescence as a 
risk factor for later life depression. Future studies should further examine causality of effects in 
larger samples. 
 
 
 
 
 
 
 
3 
 
INTRODUCTION 
Understanding the nature of the association between use of cannabis, the most widely used illicit 
drug worldwide (UNODC, 2015), and depressive disorders is important while considering health 
policies involving cannabis, because depressive disorders are the leading contributor to the 
global burden of disease attributable to mental and substance use disorders(Whiteford et al., 
2013). While evidence is fairly consistent in support of cannabis use as a risk factor for the 
development of psychosis (Moore et al., 2007) and its relapse (Patel R et al., 2016, Schoeler et 
al., 2016b, Schoeler et al., 2016a), little consensus exists regarding its association with 
depressive disorders. This is particularly important in light of marked shifts in public attitudes to 
cannabis use and its legal standing in society in many countries (Benac and Caldwell, 2013). 
Although studies have reported feelings of depression, tiredness, lack of motivation, low energy 
and anxiety as the most commonly reported negative experiences in cannabis users (Reilly et al., 
1998) and cross-sectional evidence suggests that higher levels of depressive symptoms may be 
associated with cannabis use (Schoeler et al., 2015), uncertainty remains regarding the precise 
nature of this relationship. For instance, integrating data from 4 different cohorts, Horwood et al. 
(2012) reported that two of the cohorts suggested that cannabis use leads to the development of 
depression, a third cohort suggested that depression leads to cannabis use, while the fourth one 
did not find that either of those relationships were significant when employing longitudinal 
modelling. Another integrative analysis (Silins et al., 2014) using participant-level data from 3 of 
these cohorts did not find any association with depression by age 25, when they adjusted for 
potential confounders. 
Other investigations that have tested the direction of this association (whether cannabis use leads 
to depression or vice versa) in the same sample yielded similarly contradictory results. Some 
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suggest that cannabis use leads to depression (Hayatbakhsh et al., 2007), while others suggest 
that depression leads to increase(Feingold et al., 2015) or even decreases (Womack et al., 2016) 
in cannabis use. One study did not find any significant association (Repetto et al., 2008) and 
another one reported a bi-directional relationship between cannabis use and depression severity 
(Baggio et al., 2014). Similarly, results from investigations which tested a unidirectional 
hypothesis about the nature of this association in their sample are equivocal, with some 
suggesting that depression is a risk factor of subsequent cannabis use (Wittchen et al., 2007) 
while a larger number suggest that cannabis use is a risk factor for subsequent depression (Brook 
et al., 2002, Gage et al., 2015) (for a summary of observational studies  see sTable 1., 
Supplementary Material).  
A recent meta-analysis of longitudinal studies suggest moderate effects of cannabis use on the 
risk of development of depression (Lev-Ran et al., 2014), though confidence in these effects was 
offset by large variability across studies as well as methodological concerns. On balance, this 
suggests that the possibility of other unobserved sources of confounding, such as a common 
genetic liability influencing both cannabis use and depression cannot be ruled out (Lynskey et 
al., 2004).  Studies that have explored dose-response relationships either did not find a 
significant effect of frequency of cannabis use on depression (Feingold et al., 2015, Repetto et 
al., 2008) or found evidence in support of a dose-response relationship (Brook et al., 2002, Gage 
et al., 2015). Other evidence reported that the ratio between delta-9-tetrahydrocannabinol (THC), 
the main psychoactive ingredient in the cannabis plant, and cannabidiol (CBD), the other main 
cannabinoid present in the extract of cannabis (i.e. the THC:CBD ratio) was not linked to 
depression scores in users (Schubart et al., 2011). This is supported by experimental studies that 
did not find that the administration of THC increased depressive symptoms in healthy subjects 
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(Englund et al., 2015). Another important determinant of the effect of cannabis, i.e., use during a 
sensitive developmental period (Pope et al., 2003), was not considered by a majority of the 
studies. Among the few studies that included age of onset of cannabis use in their analyses, some 
found more adverse effects if started at a younger age (Hayatbakhsh et al., 2007, Horwood et al., 
2012), while most were not indicative of moderating effects of age of onset of cannabis use on 
risk of depression (Horwood et al., 2012, Lev-Ran et al., 2014). 
The main limitation of evidence to date is the lack of a life-span prospective design, combined 
with multi-wave assessments to follow up a cohort of individuals. Such an approach makes it 
possible to investigate the question of whether later life depression results from early onset 
cannabis use. This is particularly crucial as although cannabis use commonly starts in early or 
mid-adolescence (Wagner and Anthony, 2002), a diagnosis of depressive disorder typically 
manifests in middle or later life (Kessler et al., 2007). However, most studies to date have 
examined cohorts comprising only adolescents or young adults, with a maximum follow-up age 
of 34 years (cf. sTable 1., Supplementary Material), thus limiting their ability to detect the 
incidence of depression, a substantial proportion of which is likely to have onset beyond the 
follow-up period of these studies. This may largely explain the conflicting nature of association 
observed in previous studies. In the present study, we have addressed these limitations by 
employing a prospective, multi-wave, life-span cohort design (including more than 40 years of 
follow-up, to age 48). Specifically, we investigated the effects of cannabis use on the risk of 
developing a Major Depression Disorder (MDD) (First et al., 1998) by age 48, by: 
(1) assessing the magnitude of the association between cannabis use and depression 
(2) exploring whether the effects vary across different developmental stages 
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(3) controlling for important observed confounders (other illicit drug use, comorbid mental 
disorder, employment status) and unobserved time-invariant sources of confounding in 
multiple fixed-effects analyses 
(4) investigating the directionality of the association between cannabis use and depression  
METHODS  
Study sample  
The Cambridge Study in Delinquent Development (CSDD) is a prospective longitudinal study of 
the development of offending and antisocial behaviour in a cohort of 411 boys born mostly in 
1953 and living in an ethnically homogeneous, working-class urban area of London (Farrington 
et al., 2006). They represented the complete population of boys who were 8 years old at that time 
(1961/62) and were attending one of six primary schools in a deprived area in London. Multiple 
waves (T1- T7) of data collection, which included participant interviews [at ages 8 (T1), 10 (T2), 
14 (T3), 16 (T4), 18 (T5), 32 (T6) and 48 (T7)] complemented information obtained from 
parents (annually) and teachers (bi-annually) between ages 8 and 15 years. 97% of the sample 
was white and most were raised in two-parent working class households. A detailed description 
of the methods is included as supplementary material (cf. sAppendix 1., Supplementary 
Material). The study was approved by the Ethics Committee of the Institute of Psychiatry, 
Psychology & Neuroscience. 
 
Measures  
Lifetime diagnosis of Major Depressive Disorder (MDD) and age of onset of MDD were 
assessed by a psychiatrist using the Structured Clinical Interview for DSM-IV (Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition) Axis I Disorders (SCID I) (First et al., 1998) 
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as part of a psychiatric interview at T7. Frequency of cannabis use was assessed at T3, T5, T6 
and T7. The cannabis use predictor was coded as a categorical variable that took into account age 
of first reported use [early-onset user (reported use at age 18 or before) vs. late-onset user 
(reported use subsequent to age 18)] and frequency of use [high-frequency user (> 450 times 
used across T3, T5, T6, T7) vs. low-frequency user (< 450 times used)]. This cut-off was chosen 
to generate a “high-frequency” cannabis group based on cannabis use pattern reported by our 
sample, here defined as greater than twice the third quantile (Q3) for number of times used [Q3 = 
200 times used in those who used it at least once in their lifetime]. Covariates included in the 
simple analysis were chosen based on previous research, including alcohol, cigarette and other 
illicit drug use, socioeconomic status, other psychiatric illness, behavioural and emotional 
problems in childhood, childhood anxiety and childhood conduct problems (for details see 
sAppendix 1, Supplementary Material). Those variables were included as binary variables, for 
which the higher category was indicative of disadvantage (e.g. low socioeconomic status, 
presence of childhood anxiety). 
 
Statistical methods 
Data was analysed using R3.1.3 comprising three main statistical approaches, which are 
described in more detail in the sAppendix 1 (Supplementary Material): First, simple logistic 
regression analysis to estimate the effect of cannabis use group on risk of subsequent diagnosis 
of MDD (presence vs. absence of MDD by age 48). Multiple regression analysis was carried out 
including those co-variates that were significantly (p<0.05) associated with risk of MDD in chi-
square tests (sTable 4., Supplementary Material). Second, simple and multiple Cox proportional 
hazard regression analysis was employed to test whether the time until diagnosis of MDD was 
8 
 
significantly different between the different cannabis use groups. The proportional hazards 
assumption was checked, confirming that the assumption of proportionality was not violated for 
any of the variables included. Third, fixed-effects logistic regression models were fitted in order 
to extend the ordinary logistic regression by adjusting for time-invariant, non-observed, fixed 
factors that vary across individuals. In order to investigate the potential moderating effect of age 
of onset and frequency of use, we set up two developmental dependent models, including one 
that assessed the effect of changes in cannabis frequency on risk of development of MDD within 
the age range of 14-18 years, one within the age range of 18-32 years and one within the age 
range of 32-48 years. We ran a second set of fixed-effects models, in order to investigate any 
effect that may have occurred in the reverse direction. In the multiple regression models we 
included other illicit drug use, presence of other mental illness and employment status at age 48 
as random-effects. 
 
RESULTS 
Out of the 411 boys assessed at baseline, complete multi-wave cannabis use and depression data 
(T1-T7) at follow up (age 48) was available for a total number of N=285 (for follow-up flow 
chart see sFigure 1., Supplementary Material). Comparison of subjects with and those without 
complete data who were not included in the present analyses carried out, revealed that there were 
no significant differences between the two groups in early life demographic variables (substance 
use, antisocial behavior, conduct problems, social class, anxiety), later life outcomes (substance 
use and mental health outcomes (DSM-IV based) including depression, anxiety disorders, 
substance use disorders) and cannabis use across the life span (age 18, 32 and 48) (sTable 3., 
Supplementary Material). As shown in Table 1., cannabis use was common in this sample, 
9 
 
comprising a proportion of 38.2% of subjects who used the substance at least once upto age 48. 
The majority of subjects who had ever used cannabis started using the substance between ages 
14 and 18 (76%). Although most of the early-onset cannabis users used the substance only 
around this age (51.8%) and did not continue subsequently, a quarter continued to use the 
substance subsequently (i.e. 24.1%reported use also at ages 32 and 48).  A total of 58 subjects 
(20.4%) received a diagnosis of MDD by the age of 48, with an estimated mean age of onset of 
illness of 38.57 (SD 7.13). Significant (p< 0.05) associations with risk of depression in 
exploratory analyses were found for cannabis use (ever used), other illicit drug use (ever used by 
age 32), other diagnosis of mental illness at age 48 and employment status at age 48 (cf. sTable 
4., Supplementary Material). 
 
==================== TABLE 1.  ABOUT HERE ============================ 
Simple logistic regression analysis (Table 2.) revealed that those who had never used cannabis 
had the lowest risk for developing a depressive disorder, whilst the highest risk estimates were 
found for those who had an early onset of cannabis use (age 18 or before) and continued to use 
the substance throughout their life (cumulative use endorsed more than 450 times) (OR= 
10.07[95% CI 2.33-51.61], p=0.002). The risk was reduced in magnitude but still significant for 
early-onset users who used cannabis less frequently throughout their life (OR= 2.67[95%CI 1.39-
5.12], p=0.003). Alternative specifications of cut-off for defining low frequency and high 
frequency use for the early-onset and late-onset users did not change the direction of these results 
(data available on request). After controlling for potential confounders that were significantly 
associated with depression in simple analyses, including other illicit drug use, presence of other 
mental health illness and employment status, the effects of cannabis use remained significant for 
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early-onset, high-frequency users (OR=8.83[95%CI 1.29-70.79], p=0.03; Table 2.) as well as for 
early-onset-low-frequency users (OR=2.41[95%CI 1.22-4.76], p=0.01). Including anxiety 
reported at age 14 and presence of a lifetime diagnosis of anxiety or other stress disorders in this 
model did not alter the results (cf. sTable 5. and sTable 6., Supplementary Material). In line with 
these results, Cox regression models (cf. Table 3.; Figure 1) showed that early-onset cannabis 
use was associated with a shorter time to onset of MDD for both low-frequency ([HR=2.09 
[95%CI 1.16-3.74], p=0.01) and high-frequency cannabis users ([HR=8.69 [95%CI 2.07-36.52], 
p=0.003).  
 
==================== TABLE 2.  ABOUT HERE ============================ 
 
==================== TABLE 3.  ABOUT HERE ============================ 
 
==================== FIGURE 1 ABOUT HERE ============================ 
 
As shown in Table 4., the results from the multiple, cross-lagged, fixed-effects models suggest 
that an increase in cannabis use frequency between ages 14-18 was associated with increased 
odds for the development of MDD in both early adulthood (age 18-32) by 1.08[95% CI 1.03-
1.12] (p=0.0008) and subsequently (age 33-48) by 1.20[95%CI 1.10-1.31] (p<0.0001). Changes 
in cannabis use frequency at later life stages were not significantly associated with the 
development of subsequent depression. For instance, a change in cannabis frequency between 
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age 18-32 was not a predictor for the development of MDD between age 33 to 48 (1.05[95%CI 
0.99-1.11], p=0.10). To explore the issue of reverse causation (i.e. whether cannabis use predicts 
outcome and vice versa, in the form of a two-way causal relationship), we also tested whether the 
development of MDD was associated with subsequent changes in the frequency of cannabis use. 
A diagnosis of MDD between age 18 to 32 was linked to a reduction in frequency of cannabis 
use between ages 32 and 48 by 0.72[95%CI 0.57-0.92] (p=0.009).  
 
==================== TABLE 4.  ABOUT HERE ============================ 
 
DISCUSSION 
These results provide for the first time evidence suggesting early but not late onset cannabis use 
may be a risk factor for the subsequent development of major depressive disorder. We observed 
an effect that was not confounded by other observed and unobserved time-invariant risk factors 
such as shared genetic or environmental influences or factors that change over time such as the 
use of other substances or the presence of comorbid psychiatric illness. Adverse effects of 
cannabis use on the risk of development of MDD and on time until MDD diagnosis were present 
only in those who had used it at a younger age (before age 18) with the effects being greater in 
high-frequency user (OR 8.83 / HR 8.69, p<0.05) than in low-frequency users (OR 2.41 / HR 
2.09, p<0.05), while no significant adverse effects were present if cannabis use was initiated at 
an older age (age 27 onwards) (cf. Table 2. and Table 3.).  Early-onset, high-frequency cannabis 
users experienced depression more than 5 years earlier compared to never users (41 vs. 46.65 
years). This is consistent with the idea of developmental sensitivity to the adverse effects of 
cannabis (Pope et al., 2003), as well as with the results of our fixed-effects (FE) analysis. The 
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risk of developing subsequent depression was predicted only by an increase in cannabis use 
during adolescence (between ages 14 and 18) but not early adulthood (between ages 18 and 32) 
or subsequently (use between ages 32 and 48). In addition, the results suggest that the effect of 
early-onset cannabis use cannot be explained by unobserved time-invariant sources of 
confounding such as shared genetic or stable environmental factors. This may also explain why 
previous longitudinal analyses of panel data in younger cohorts (up to the maximum age of 34, 
cf. sTable 1., Supplementary Material) have been inconclusive as to whether an increase of 
cannabis use leads to an increase in risk of depression over time(Horwood et al., 2012, Silins et 
al., 2014), even when dose-response patterns were tested(Repetto et al., 2008, Womack et al., 
2016). Since cigarette use across the life-span was not significantly linked to the risk of MDD, 
our results were not confounded by smoking, consistent with previous studies(Hayatbakhsh et 
al., 2007). These findings are also consistent with evidence from animal research, in which long-
term exposure of cannabinoids resulted in depression-like symptoms only in adolescent but not 
adult rats(Bambico et al., 2010). Interestingly, cross-lagged, fixed-effects analysis revealed that a 
diagnosis of MDD in adulthood (age 18-32) was predictive of reduction in cannabis use 
subsequently, which is consistent with evidence from a recent longitudinal study(Womack et al., 
2016). While subsequent reduction in cannabis use may have been a result of depressed 
individuals receiving specific therapeutic input following contact with health services as a result 
of their depression, this was not specifically examined. While these results cannot completely 
rule out the possibility that depression may also lead to cannabis use (Horwood et al., 2012, 
Wittchen et al., 2007), e.g. as a form of self-medicating behaviour, this seems less likely. This is 
also in line with a previous meta-analysis reporting overall significant adverse effects of 
cannabis use on depression outcome (OR 1.17), with more pronounced effects being present in 
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heavier users (OR 1.62) (Lev-Ran et al., 2014).  As we cannot completely rule out the possibility 
that depression occurring early on in life led to subsequent initiation or continuation of cannabis 
us, these results should be treated with caution and future studies should investigate more 
thoroughly the bi-directional pathways between cannabis use and depression in order to 
definitively rule out the possibility of reverse causation, as in previous longitudinal studies 
examining causal nature of associations with cannabis use (Schoeler et al., 2016b, Schoeler et al., 
2016c). Since we investigated different groups of cannabis-using subjects based on their usage 
pattern, future studies may also evaluate continuous measures of cannabis use, such as the 
number of joints smoked over specified life-periods. These results are to be considered against 
certain limitations of this study, such as comprising a select group of predominantly white males 
who grew up in a working class urban environment in the 1960s and 1970s. Therefore, the 
results may not generalize to the wider population and in particular to females, those from other 
ethnicities, individuals brought up in rural environments or children from different socio-
economic status. Future studies should therefore expand on this and include individuals from 
more heterogeneous backgrounds. Another limitation is the use of self-report measures of 
cannabis and other substance use leading to potential under-reporting and the inclusion of only 
modestly sized cannabis-user groups. The relatively modest size of our sample limits our ability 
to conclude with certainty that late-onset cannabis use does not increase the risk of depression 
over the long-term. However, sensitivity analysis carried out by combining the two late-onset 
groups in order to increase sample power did not change the conclusion (ORlate-onset=1.15, 
p=0.81). Although attrition in this sample was relatively low (Rocque et al., 2017), only the 
subsample for whom complete information on SCID I was available was included in our study. 
This reduced the sample size for the present analyses and may have induced bias in our 
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estimates. However, non-assessed subjects were not strictly drop-outs and, hence, it is unlikely 
that this reflects a systematic bias linked to individual characteristics that would have 
confounded the association between cannabis use and risk of development of depression. This is 
also supported by the fixed effects analysis, which has the advantage of controlling for all 
unobserved time-invariant individual factors and confirmed the results from our multivariate 
models. Future studies should therefore include larger samples to assess the association between 
different trajectories of cannabis use and the risk of depression. Although we assessed a range of 
covariates at various time points, we cannot draw firm conclusions on whether or when other 
mediating or modifying factors impact on the relationship between cannabis use and risk of 
development. The lack of consideration of other potential unmeasured time-variant factors that 
cannot be accounted for in fixed-effects models (e.g. epigenetic phenomena) could have also 
affected the results. For instance, despite the use of longitudinal panel data, this design does not 
allow us to make definitive conclusions regarding causality since fixed-effects models can 
neither account for individual unmeasured factors that vary over time nor do they address 
sufficiently the possibility of reverse causality. However, as discussed in greater detail as part of 
supplementary material (Appendix 3.), these factors are unlikely to have affected the direction of 
results presented here. Regarding the assessment of cannabis use, it is worth noting at the outset 
that the present cohort study was initiated several decades ago, much before the population level 
effects of cannabis and other drug use began to be systematically measured. Hence, assessments 
of exposure were perhaps less optimal than if one were to initiate such a cohort now. Finally, it 
should be pointed out that MDD was only assessed at the last follow-up assessment (at age 48), 
which may have resulted in under-reporting. However, this is unlikely to have systematically 
affected either the cannabis unexposed or exposed groups or the early-onset or late-onset 
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subgroups of cannabis users. Similarly, if self-reported cannabis use had been under-reported by 
users, which is usually not the case as data from studies that validated self-report information 
with biological tests suggest (Di Forti et al., 2012, Basurto et al., 2009, Denis et al., 2012), this is 
likely to have resulted in an underestimation of effect size. Hence, it is unlikely that under-
reporting as a result of recall bias would have affected the direction of relationship that we have 
observed. It should also be pointed out that we included only a relatively conservative outcome 
measure (presence of DSM-based diagnosis of MDD), for which reason we could not estimate 
the effect of cannabis use on more subtle depressive symptomatology across the life-span. 
Furthermore, we were not able to control for the effect of early life sub-clinical depressive or 
other affective symptomatology that predate the first onset of depression in our models. 
However, we attempted to address the possibility that early emotional disturbance or 
dysregulation may have in turn led to early onset cannabis use, we examined whether anxiety at 
age 14 was predictive of subsequent cannabis use, which was not the case when we tested the 
association for cannabis use reported at age 16 (p=0.29), age 18 (p=0.74), age 32 (p=0.74) or age 
48 (p=0.21). Hence, future studies should use multi-point assessments across the life-span to 
prospectively assess depressive outcomes both in terms of syndromal disorder as well as 
depressive symptoms as done in previous studies in young adults (Horwood et al., 2012) as well 
as include biological validation of the predictor of interest i.e., cannabis use. Future studies 
should also investigate other potential risk factors such as poor coping or emotional 
dysregulation that may influence or mediate the effects of cannabis use on risk of depression. 
Since the THC levels in the cannabis have increased in recent years (Mehmedic et al., 2010, 
ElSohly et al., 2016), with THC being only one of the more than 80 different cannabinoids 
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identified to date (ElSohly and Gul, 2014), future investigations should also distinguish between 
different types of cannabis that differ in their potency and cannabinoid constituents.  
In summary, we found that cannabis use, especially during a developmentally sensitive period of 
life is associated with subsequent risk of developing major depression after controlling for 
potential confounders, suggestive of a potential causal relationship, although future 
investigations on this topic are necessary in order to draw more definite conclusions. These 
results have important public health implications given that depressive disorders are one of the 
top ten causes of disability in the world (Whiteford et al., 2013). 
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Table 2. Cannabis profiles and risk of subsequent MDD: Logistic regression analyses* 
Simple logistic regression (N=284) OR 95% CI p 
Cannabis late onset – low frequency 0.71 0.11 – 2.69 0.66 
Cannabis late onset – high frequency 3.02 0.40 – 16.34 0.22 
Cannabis early onset – low frequency 2.67 1.39 – 5.12 0.003 
Cannabis early onset – high frequency 10.07 2.33 – 51.61 0.002 
Multiple logistic regression (N=284) OR 95% CI p 
Cannabis late onset – low frequency 0.68 0.10 - 2.65 0.63 
Cannabis late onset – high frequency 2.23 0.26 - 14.94 0.42 
Cannabis early onset – low frequency 2.41 1.22 - 4.76 0.01 
Cannabis early onset – high frequency 8.83 1.29 - 70.79 0.03 
Other mental illness (yes) 2.18 1.15 - 4.14 0.02 
Other illicit drug use (yes) 1.10 0.28 - 3.75 0.88 
Employment status (unemployed) 2.34 1.19 - 4.53 0.01 
Note.  Reference group = never cannabis users; Early onset = Cannabis use at age 18 or before; High frequency 
= > 450 cumulative number of times used across time points (ages 18, 32, 48) 
*n=1 cases excluded since MDD was diagnosed prior to cannabis use 
Table(s) Click here to download Table(s) Table 2. Simple_Multiple
Logistic Regression_PsychMed.docx
 Table 3.  Cannabis profiles and time until subsequent MDD: Hazard ratios (HR)* 
Simple Cox Regression (N=284) HR 95% CI p 
Cannabis late onset – low frequency 1.05 0.32-3.49 0.93 
Cannabis late onset – high frequency 2.90 0.69-12.25 0.15 
Cannabis early onset – low frequency 2.26 1.27-4.01 0.005 
Cannabis early onset – high frequency 6.65 2.54-17.41 0.0001 
Multiple Cox Regression (N=284) HR 95% CI p 
Cannabis late onset – low frequency 1.06 0.32-3.54 0.92 
Cannabis late onset – high frequency 2.77 0.61-12.51 0.19 
Cannabis early onset – low frequency 2.09 1.16-3.74 0.01 
Cannabis early onset – high frequency 8.69 2.07-36.52 0.003 
Other mental illness (yes) 1.78 1.05-3.03 0.03 
Other illicit drug use (yes) 0.73 0.25-2.15 0.56 
Employment status (unemployed) 1.97 1.14-3.41 0.02 
Note.  Reference group = never cannabis users; Early onset = Cannabis use at age 18 or before; High frequency 
= > 450 cumulative number of times used across time points (ages 18, 32, 48) 
*n=1 cases excluded since MDD was diagnosed prior to cannabis use 
Table(s) Click here to download Table(s) Table 3. Simple_Multiple
Hazard Regression_PsychMed.docx
 Table 4. Fixed effects regression analysis  
 Univariate Multivariate* 
 OR 95% CI p OR 95% CI p 
Effect of Cannabis frequency on MDD in young adolescence (age 18 – 32) 
Cannabis frequency (age 14 - 18) 1.08 (1.04 – 1.13) 0.0002 1.08 (1.03 – 1.12) 0.0008 
Cannabis frequency (age 18 - 32) 1.02 (1.00 – 1.05) 0.07 1.01 (0.99 – 1.05) 0.32 
Effect of Cannabis frequency on MDD in adulthood (age 32 – 48) 
Cannabis frequency (age 14 - 18) 1.22 (1.12 – 1.33) <0.0001 1.20 (1.10 – 1.31) <0.0001 
Cannabis frequency (age 18 - 32) 1.07 (1.02 – 1.13) 0.007 1.05 (0.99 – 1.11) 0.10 
Cannabis frequency (age 32 - 48) 1.04 (0.99 – 1.09) 0.17 1.01 (0.95 – 1.07) 0.76 
 Univariate Multivariate* 
 Est. 95% CI  Est. 95% CI  
Effect of MDD on cannabis frequency in adulthood (age 32 – 48) 
MDD (age 18 - 32) 0.77 (0.59 – 0.99) 0.05 0.72 (0.57 – 0.92) 0.009 
MDD (age 32 - 48) 1.07 (0.94 – 1.21) 0.33 1.02 (0.90 – 1.15) 0.77 
Note. Increase in frequency = increase in one unit [(0) non-user; (1) low frequency user; (2) high frequency user] 
*Controlled for random effects, including (1) other psychiatric illness and (2) other illicit drug use, (3) employment status at age 48 
Table(s) Click here to download Table(s) Table 4. Simple_Multiple
Fixed Effects Regression_PsychMed.docx
Table 1. Cannabis and depression trajectories (N=285) 
Age of onset MDD 
Diagnosis of MDD 
Mean in years (SD) 
Ever diagnosed (yes) (n) 
38.57 (7.13) 
20.4% (58) 
    Before 18 (n) 
   Between 18-32 (n) 
   Between 33-48 (n) 
  0% (0) 
  22.4% (13) 
  77.6% (45) 
Cannabis use trajectory Ever used (yes) 
  Onset up to 14 (n) 
  Onset between 15-18 (n) 
  Onset between 27-32 (n)  
  Onset between 43-48 (n) 
38.2% (109) 
  0% (0) 
  76.1% (83) 
  13.8% (15) 
  10.1% (11) 
Cannabis use pattern Never used (n) 61.8% (176) 
Late onset – low frequency (n) 0.08% (22) 
Late onset – high frequency (n) 0.01% (4) 
Early onset – low frequency (n) 0.27% (78) 
Early onset – high frequency (n) 0.02% (5) 
Cannabis-Depression Trajectory Cannabis Æ MDD 32 (11.3%) 
 Cannabis Æ no MDD 75 (26.3%) 
 Never cannabis, no MDD 152 (53.3%) 
 Never cannabis Æ MDD 25 (8.8%) 
 MDD Æ Cannabis 1 (0.4%) 
Note. MDD = Diagnosis of Major Depression Disorder based on Structured Clinical Interview for DSM-IV 
Axis I Disorders (SCID-I) 
 
Table(s) Click here to download Table(s) Table 1.
Demographics_PsychMed_R1.docx
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H
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et al. 
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TP / 
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(T1-T2) 
C
2: Frequency of cannabis use 
(T2-T3) 
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D
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D
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D
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Severity 
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A
LSPA
C
 = A
von Longitudinal Study of Parents and C
hildren (B
oyd et al., 2012); A
TP = The A
ustralian Tem
peram
ent Project (Prior et al., 2000); A
TR
 = A
ustralian Tw
in R
egister (Lynskey et al., 2004); A
U
D
A
D
IS-IV
 = A
lcohol U
se 
D
isorder and A
ssociated D
isabilities Interview
 Schedule (G
rant et al., 2003a); B
D
I = B
eck’s D
epression Inventory (B
eck et al., 1987); B
EC
A
 = B
altim
ore Epidem
iologic C
atchm
ent A
rea study (A
nthony and H
elzer, 1991); B
SI = B
rief 
Sym
ptom
 Inventory (D
egoratis and Spencer, 1982); C
ES-D
 = C
entre for Epidem
iological Studies - D
epression Scale (R
adloff, 1977);  C
IC
 = C
hildren in the C
om
m
unity sam
ple (B
rook et al., 2002); C
H
D
S = The C
hristchurch H
ealth and 
D
evelopm
ent Study (Fergusson and H
orw
ood, 2001); C
ID
I = C
om
posite International D
iagnostic Interview
 (R
obins et al., 1983); C
IS = C
linical Interview
 Schedule (Lew
is et al., 1988); C
IS-R
 = com
puterized revised C
linical Interview
 
Schedule (Lew
is et al., 1992); C
-SU
R
F = C
ohort Study on Substance U
se R
isk Factors (B
aggio et al., 2014); C
U
D
 = C
annabis U
se D
isorder; D
A
SS = D
epression A
nxiety Stress Scale (Lovibond and Lovibond, 1995); D
IC
A
 = D
iagnostic 
Interview
 for C
hildren and A
dolescents (R
eich, 2000); D
IS = D
iagnostic Interview
 Schedule (R
obins et al., 1981); D
ISC
 =  D
iagnostic Interview
 Schedule for C
hildren (C
ostello et al., 1982); D
M
H
D
S = D
unedin M
ultidisciplinary H
ealth and 
D
evelopm
ent Study (Silva and Stanton, 1996); EC
D
 = Epidem
iologic C
atchm
ent A
rea Program
 (Tien and A
nthony, 1990); ED
SP = Early D
evelopm
ental Stages of Psychopathology (W
ittchen et al., 1998); FEM
 = Fixed Effects M
odel; G
D
S 
= G
oldberg D
epression Scale (G
oldberg et al., 1988); JH
U
-R
T = John H
opkins U
niversity – R
andom
ized Trial (H
arder et al., 2008); LA
T = Life A
cross Tim
e: A
 Longitudinal Study; LSEC
D
 = Longitudinal Study of Ego and C
ognitive 
D
evelopm
ent (B
lock and B
lock, 1980);  M
 = M
ean; M
U
SP = M
ater U
niversity Study of Pregnancy (N
ajm
an et al., 2005); N
ESA
R
C
 = N
ational Epidem
iologic Survey on A
lcohol and R
elated C
onditions (G
rant et al., 2003b); M
TFS = 
M
innesota Tw
in Fam
ily Study; N
ESPA
R
 = N
ational Epidem
iologic Survey on A
lcohol and R
elated C
onditions (B
lanco et al., 2016); N
EM
ESIS = N
etherlands M
ental H
ealth Survey and Incidence Study; N
SM
H
W
 = N
ational Survey of 
M
ental H
ealth and W
ellbeing (Saw
yer et al., 2000); O
C
H
S = O
ntario C
hild H
ealth Study (B
oyle et al., 1987);  PA
R
T (by Sw
edish acronym
) = M
ental H
ealth, W
ork and R
elations study (D
anielsson et al., 2016); PA
TH
 = The Personality and 
Total H
ealth Study (A
nstey et al., 2011); PM
C
P = Pitt, M
other &
 C
hild Project (Shaw
 et al., 2003); R
 = R
ange; SC
L = John H
opkins Sym
ptom
 C
hecklist (D
erogatis, 1992); SC
ID
 = Structured C
linical Interview
 for D
SM
-III-R
 (Spitzer et al., 
1987); SD
U
SA
P = Student D
rug U
se Survey in the A
tlantic Provinces ; SEM
 = Structural Equation M
odel; SM
FQ
 = Short M
ood and Feelings Q
uestionnaire (A
ngold et al., 1995); SSA
G
A
 = Sem
i-Structured A
ssessm
ent for the G
enetics of 
A
lcoholism
 (Lynskey et al., 2004); T = Tim
e point of assessm
ent; U
SN
C
S = U
nited States N
ational C
om
orbidity Study (K
essler, 1994); V
A
H
C
S = V
ictorian A
dolescent H
ealth C
ohort Study (Patton et al., 2007); W
H
O
-M
D
I = W
orld H
ealth 
O
rganization – M
ajor D
epressive Inventory (B
ech et al., 2001); W
M
H
S = W
orld M
ental H
ealth Survey (K
essler and Ü
stün, 2008); Y
A
SR
 = Y
oung and A
dult Self-R
eport (A
chenbach, 1997); Y
N
LS = Y
oung in N
orw
ay Longitudinal Study 
(Pedersen, 2007). 
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sAppendix 1. Methods 
 
Study sample 
The Cambridge Study in Delinquent Development (CSDD), originally designed by Donald J. West and 
directed since 1982 by David P. Farrington, is a prospective longitudinal study of the development of 
offending and antisocial behavior in a cohort of 411 boys born mostly in 1953 living in a homogeneous, 
working class urban area of South London [a review of major findings may be found in several books (West 
and Farrington, 1977, West and Farrington, 1973, West, 1982, West, 1969, Piquero et al., 2007, Farrington 
et al., 2013, Farrington et al., 2009) as well as in several summary papers (Farrington et al., 2006a, 
Farrington, 1995, Farrington and West, 1990)]. The sample comprised a complete population of boys from 
six primary schools who were aged 8-9 in 1961/62 in a deprived area in South London. Most of the boys 
(357, 87%) were White in appearance and of British origin(Farrington et al., 2006b). There were multiple 
waves (T1- T7) of data collection which included participants being interviewed in their school [at ages 8 
(T1), 10 (T2), 14 (T3), in research offices (at ages of 16 (T4) and 18 (T5)] or in their homes (at ages 32 (T6) 
and 48 (T7)] by social science graduates. Parents were interviewed (about once per year) and questionnaires 
were completed by the boys’ teachers (about once every two years) between ages 8 and 15 to complement 
information about troublesome/aggressive behavior in school and difficulties at home.  
 
Measures 
Presence of Major Depressive Disorder (MDD) 
Lifetime diagnosis of Major Depressive Disorder (MDD) and age of onset of MDD were assessed by a 
psychiatrist using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First et al., 
1998) as part of a psychiatric interview at T7. Subjects were classified as those with or without a lifetime 
diagnosis (MDD) by age 48 (T7).  
Cannabis use  
Cannabis use at the ages of 14 (T3) and 18 years (T5) was assessed in terms of frequency of use (number of 
times used in past 6 months) and ever used (vs. never used) before that time-point of assessment. Cannabis 
use at ages 32 (T6) and 48 years (T7) was assessed in terms of frequency of use (number of times used in 
the preceding 5 years) and presence (vs. absence) of use (used more than once in the 5 years preceding the 
interview). 
Covariates  
Covariates included in the simple analysis were chosen based on previous research, reporting a link between 
depression and: 
(1) Alcohol use (Brook et al., 2002, Bovasso, 2014):  
a. Self-reported presence (vs. absence) of binge drinking ( at least 13 units of alcohol drunk in one 
evening in the last month yes/no) was assessed at T5, T6, and T7 and an ordinal variable was 
computed based on whether binge-drinking was present or not at each of the 3 time-points 
assessed (score ranging from 0-3).   
b. Presence (vs. absence) of a DSM-IV lifetime diagnosis of alcohol use and/or dependence was 
assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First et 
al., 1998) as part of the psychiatric interview conducted at age 48 (T7). 
(2) Cigarette use (Brook et al., 2002, Georgiades and Boyle, 2007, Pedersen, 2007): Self-reported 
cigarette use defined as presence of smoking (over 20 cigarettes/ day) was assessed at T5, T6 and T7 
and a score (from 0 to 3) was computed based on whether smoking was present or not at each of the 
3 time-points assessed (scored from 0 - 3).   
(3) Other illicit drug use (Brook et al., 2002):  
a. Self-reported presence (vs. absence) of illicit drug use (other than cannabis) was assessed at T6 
(used > 1 prior to age 32) and was coded as a dichotomized variable. 
b. DSM-IV diagnosis of substance use and/or dependence other than cannabis use disorder was 
assessed using the SCID-I as part of the psychiatric interview at age 48 (T7).  
(4) Socioeconomic status (Lorant et al., 2003): Social class assessed at age 10 (T2) was coded as “low” 
if the family breadwinner had an unskilled manual job. Social class assessed at age 48 (T7) was 
coded as “low” if a subject had an unskilled manual job or was not working.  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(5) Employment status: Employment status assessed at age 48 was coded as “unemployed” if there was 
a period of > 5 months of unemployment in the last 5 years. 
(6) Other psychiatric illness: Presence (vs. absence) of a diagnosis of mental illness other than 
depression or substance abuse/dependence was assessed using the SCID-I as part of a psychiatric 
interview at age 48 (T7). sTable 2. displays the prevalence rates of other DSM diagnoses in the 
sample. 
(7) Behavioural and emotional problems in childhood (Rey et al., 2002, Windle and Wiesner, 2004, De 
Graaf et al., 2010) including: 
a. Antisocial personality: Antisocial traits were assessed at age 10 (T2) based on teacher, peer, or 
parent ratings using the antisocial personality scale (AP) (Farrington 1991). 
b. Childhood anxiety: Anxiety was assessed at age 10 (T2). 
c. Childhood conduct problems: Conduct problems were assessed at age 8 (T1) based on teacher 
and parent ratings of being “troublesome” and at age 14 (T3) were based on a teacher’s rating of 
being aggressive in school. 
 
Statistical methods 
Data was analysed using R3.1.3 (R Core Team, 2015) comprising three main statistical approaches:  
(1) Logistic regression analysis to estimate the effect of cannabis use group on risk of subsequent 
diagnosis of MDD (presence vs. absence of MDD by age 48). Given the focus on risk of subsequent 
MDD, we excluded one case where depression was diagnosed prior to the reported use of cannabis 
[diagnosis received at age 36, admitted to cannabis use at T7 (age 43-48) but not T6 (age 27-32)]. 
Three cases were classified as cannabis-using subjects prior to the diagnosis of MDD, although we 
were unable to establish accurately whether onset of cannabis use actually preceded the diagnosis of 
MDD [n=1 reported cannabis use at T6 (age 27-32) and received diagnosis of MDD at age 30, n=2 
reported cannabis use at T7 (age 43-48) and received diagnosis of MDD at age 44/43]. To address 
the potential effects of reverse causation, we carried out further analysis using longitudinal 
modelling that specifically elaborated on the issue of directionality (cf. fixed-effects analysis below). 
The cannabis use predictor was coded as a categorical variable that took into account age of first 
reported use [early-onset user (reported use at age 18 or before) vs. late-onset user (reported use 
subsequent to age 18)] and frequency of use [high-frequency user (> 450 times used across T3, T5, 
T6, T7) vs. low-frequency user (< 450 times used)]. This cut-off was chosen to generate a “high-
frequency” cannabis group based on cannabis use pattern reported by our sample, here defined as 
greater than twice the third quantile (Q3) for number of times used [Q3 = 200 times used in those who 
used it at least once in their lifetime]. In the regression analyses, these 4 different cannabis use 
groups were compared to a non-user group as the reference group (no reported use of cannabis at T3, 
T5, T6 and T7). Multiple regression analysis was carried out including those co-variates that were 
significantly (p<0.05) associated with risk of MDD in chi-square tests. 
(2) Cox proportional hazard regression analysis was employed to test whether the time until diagnosis of 
MDD was significantly different between the different cannabis use groups. Person years of follow 
up (age 0 to age 48) were used as the underlying time-scale.  Simple and multiple analyses were 
carried out, including the same categorical cannabis predictor and covariates as in the logistic 
regression analysis. The Hazard Ratio (HR) was reported for the cannabis groups, as well as all 
covariates included in the model (cf. Table 3.).The proportional hazards assumption was checked, 
revealing that the assumption of proportionality was not violated for any of the variables included. 
(3) Fixed-effects logistic regression models were fitted in order to extend the ordinary logistic regression 
by adjusting for time-invariant, non-observed, fixed factors that vary across individuals, such as 
family background, genetic influences, personality or pre-existing depressive traits. In order to 
investigate the potential moderating effect of age of onset and frequency of use, we set up two 
developmental dependent models, including one that assessed the effect of changes in cannabis 
frequency [(0) non-user; (1) low frequency user = < 150 times used at time of assessment (i.e. use 
less than Q3 per assessment); (2) high-frequency user = > 150 times used at time of assessment] on 
risk of development of MDD within the age range of 14-18 years, one within the age range of 18-32 
years and one within the age range of 32-48 years. In order to investigate any effect that may have 
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occurred in the reverse direction (i.e. reverse causation: development of MDD predisposing to a 
subsequent increase in cannabis frequency), we ran a second set of fixed-effects models that 
examined the effect of occurrence of MDD during two distinct developmental periods (diagnosis 
between 18 to 32 years and diagnosis between 33 to 48 years) as a predictor for subsequent changes 
in frequency of cannabis use. The simple and multiple regression models were fitted using the R 
package lme4 (Bates et al., 2015) for binary (risk of depression) and categorical outcomes (increase 
in cannabis frequency category). In the multiple model we included other illicit drug use and 
presence of other mental illness as random-effects. 
 
 
sAppendix 2. Supplementary Results 
Out of the 411 boys assessed at baseline, complete multi-wave cannabis and depression data (T1-T7) at 
follow up 48 years later was available for a total number of N=285 (cf. Flow chart, sFigure 1.). Comparing 
subjects that dropped out throughout follow up (n=126) to completers (n=285) in demographic variables and 
outcome data revealed that there were no significant differences between the two groups (cf. sTable1). 
 
 
sAppendix 3. Supplementary Discussion 
Certain limitations should be taken into consideration when interpreting these results. Firstly, the sample 
included a select group of predominantly white males who grew up in in a working class urban environment 
in the 1960s and 1970s, for which reason the results may not generalize to females, other ethnicities or 
social classes. This also limited our ability to investigate any potential moderating effects of gender, as 
examined in previous studies (Patton et al., 2007, Poulin et al., 2005). Despite the use of longitudinal panel 
data, this design does not allow us to make definitive conclusions regarding causality since fixed-effects 
models can neither account for individual unmeasured factors that vary over time nor do they address 
sufficiently the possibility of reverse causality. However, by exploring a range of potential confounders as 
well as by testing bi-directional cross-lagged relationships (cannabis on depression and vice versa), the 
results provide a higher level of evidence in support of cannabis use as a causal risk factor for depression 
than the majority of the prior studies. Such an analytical design is considered as a quasi-experimental design 
that is only second best to randomised control trials when identifying causal risk factors (Murray et al., 
2009).  
 
Absence of effects of late-onset cannabis use on the risk of subsequent depression may reflect a lack of 
power to detect such effect. Nevertheless, we found that the effect of changes in cannabis frequency became 
more pronounced as the age of onset of exposure decreased, suggesting that initiation of cannabis use in 
later life was associated with a lower risk of developing subsequent MDD. This was further supported by 
combining the two late-onset groups in order to increase sample power (cf. sTable 7.). Nevertheless, future 
studies including larger samples should model the effects of cannabis use at different stages across the life-
span in order to derive more precise estimates for age-dependent effects of cannabis use. The inclusion of 
more frequent follow-up assessments at shorter intervals (e.g. yearly assessments), especially in early 
neurodevelopmental stages could help explore developmental sensitivities to cannabis use in greater detail. 
In this context, future studies should also investigate the potential mechanisms of effects of cannabis over 
the life span. Furthermore, the inclusion of narrower and more numerous follow ups (e.g. yearly 
assessments), especially in early neurodevelopmental stages, could help to explore questions on 
developmental sensitivities to cannabis use in more detail.  
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sFigure 1. Follow up flow chart 
 
 
Note. SCID-I = Structured Clinical Interview for DSM-IV Axis I Disorders (First et al., 1998) 
 
 
 
 
sTable 2. Prevalence of diagnosis of other mental illness 
DSM Diagnosis Number of subjects 
diagnosed 
Percentage 
Bipolar 0/285 0% 
Schizophrenia 1/285 0.004% 
Anxiety/Stress* 77/285 27% 
Eating disorder 2/285 0.007% 
* Includes panic disorder, obsessive compulsive disorder, post-traumatic 
stress disorder, anxiety disorder, somatoform disorder, adjustment disorder 
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sTable 3. Differences in demographics and outcome in later life and between completers and drop outs 
 Complete data n/nav (%)a Incomplete data n/nav (%) a,b p 
Sample size n=285 n=126  
Cannabis variables 
Cannabis at age 18 (yes) 82/285 (29%) 27/105 (28%) 0.86 
Cannabis at age 32 (yes) 50/285 (17.5%) 19/91 (21%) 0.47 
Cannabis at age 48 (yes) 44/285 (15%) 11/80 (14%) 0.71 
Mental health outcome (DSM diagnosis) 
Lifetime diagnosis depression (yes) 58/285 (20%) 2/19 (11%) 0.30 
Lifetime diagnosis anxiety disorder (yes) 73/285 (26%) 4/19 (21%) 0.19 
Other substance use disorder (yes) 29/285 (10%) 2/19 (11%) 0.96 
Alcohol use disorder (yes) 56/285 (20%) 3/19 (16%) 0.68 
Any mental health diagnosis (yes)b 171/285 (40%) 5/19 (21%) 0.24 
Early life variables 
Alcohol use at 18 (yes) 57/285 (20%) 24/103 (23%) 0.48 
Cigarette use at 18 (yes) 78/284 (28%) 26/104 (25%) 0.63 
Antisocial Personality at age 10 (yes) 65/285 (23%) 33/126 (26%) 0.46 
Low social class at age 10 (yes) 50/285 (18%) 29/126 (23%) 0.19 
Anxiety at age 14 (yes) 25/285 (9%) 13/126 (10%) 0.62 
Conduct problems at age 14 (yes) 99/285 (35%) 35/126 (28%) 0.17 
Late life variables 
Other illicit drug use at age 32 (yes) 25/285 (9%) 11/92 (12%) 0.37 
Cigarette use at 48 (yes) 71/285 (25%) 20/80 (25%) 0.99 
Alcohol use at 48 (yes) 59/285(21%) 19/80 (24%) 0.56 
Note. p= p-value for chi-square test 
a Prevalence reported for n (number of subjects scoring “yes” for the variable of interest) out of nav (total number of 
subjects for which data was available) 
b Subjects with incomplete data include those who dropped out (n=107 that did not complete the SCID-I interview) 
and those with missing data in other variables (n=19) 
c Including bipolar, schizophrenia,  depression, panic disorder, obsessive compulsive disorder, post-traumatic stress 
disorder, anxiety disorder, somatoform disorder, adjustment disorder, any substance use disorder 
sTable 4. Childhood and life factors associated with risk of MDD by age 48 (N=284)* 
 χ2 p 
Cannabis use (ever/SR) 9.93 0.002 
Cigarette use (cum/SR)1 4.18 0.24 
Alcohol use (cum/SR) 0.03 1.00 
Alcohol (DSM Diagnosis) 3.14 0.08 
Presence other illicit substance use (SR) 6.79 0.009 
Presence substance use disorder (DSM) 1.14 0.29 
Other mental illness (DSM Diagnosis) 6.85 0.008 
Anxiety at age 14 (yes) 0.26 0.61 
Antisocial at age 10 (yes) 0.52 0.47 
Conduct problems at age 14 (yes) 1.31 0.25 
Low social class at age 10 (yes) 0.20 0.65 
Low social class at age 48 (yes) 1.13 0.29 
Employment status at age 48 (unemployed) 10.54 0.001 
 Note. DSM = Diagnosis based on Structured Clinical Interview for DSM-IV Axis I Disorders (First et al., 1998); SR = Self-reported. 
1 missing data for n=2 
*n=1 cases excluded since MDD was diagnosed prior to cannabis use 
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sTable 5. Anxiety and risk of subsequent MDD: Logistic regression analysis* 
Multiple logistic regression (N=284) OR 95% CI p 
Cannabis late onset – low frequency 0.68 0.10 – 2.65 0.63 
Cannabis late onset – high frequency 2.23 0.25 – 15.10 0.42 
Cannabis early onset – low frequency 2.41 1.22 – 4.76 0.01 
Cannabis early onset – high frequency 8.83 1.29 – 70.97 0.03 
Other mental illness 2.18 1.15 – 4.14 0.02 
Other illicit drug use 1.10 0.28 – 3.76 0.89 
Employment status (unemployed) 2.34 1.18 – 4.58 0.01 
Anxiety at age 14 1.01 0.32 – 2.81 0.99 
Note. Early onset = Cannabis use at age 18 or before; High frequency = > 450 cumulative number of times used across time points (age 
18, 32, 48) 
*n=1 cases excluded since MDD was diagnosed prior to cannabis use. Reference group = never cannabis users 
sTable 6. Anxiety/stress disorder and risk of MDD: Logistic regression analysisa 
Multiple logistic regression (N=284) OR 95% CI p 
Cannabis late onset – low frequency 0.67 0.10 – 2.62 0.62 
Cannabis late onset – high frequency 2.51 0.28 – 17.42 0.36 
Cannabis early onset – low frequency 2.43 1.22 – 4.80 0.01 
Cannabis early onset – high frequency 8.78 1.27 – 71.62 0.03 
Anxiety/Stressb 2.41 1.26 – 4.60 0.01 
Other illicit drug use 1.11 0.28 – 3.87 0.87 
Employment status (unemployed) 2.32 1.18 – 4.52 0.01 
Note. Early onset = Cannabis use at age 18 or before; High frequency = > 450 cumulative number of times 
used across time points (age 18, 32, 48) 
an=1 cases excluded since MDD was diagnosed prior to cannabis use. Reference group = never cannabis 
users 
b Includes panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, anxiety disorder, 
somatoform disorder, adjustment disorder 
sTable 7. Sensitivity analysis: Cannabis profiles and risk of subsequent MDD (Logistic regression 
analyses)* 
Simple logistic regression (N=284) OR 95% CI p 
Cannabis late onset  1.15 0.32 - 3.34 0.81 
Cannabis early onset – low frequency 2.67 1.39 - 5.12 0.003 
Cannabis early onset – high frequency 10.07 2.33 - 51.61 0.002 
Note.  Reference group = never cannabis users; Early onset = Cannabis use at age 18 or before; High 
frequency = > 450 cumulative number of times used across time points (ages 18, 32, 48) 
*n=1 cases excluded since MDD was diagnosed prior to cannabis use 
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